GlassScriptPhysician profile
Andrea Ford
NPI 1447473046
$2,662.03
in general payments reported to CMS, 2019-2025
24 companies · $143 in 2025
The $143 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $14.98 · 2021: $750 · 2022: $349 · 2023: $404 · 2024: $1,001 · 2025: $143.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,548.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,547.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $401.75 | 2021-2024 | Vraylar, Ubrelvy |
| Lilly USA, LLC | $389.08 | 2020-2024 | Jardiance, Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $364.40 | 2021-2025 | Breztri, Airsupra |
| Amgen INC. | $352.19 | 2021-2025 | Otezla, Repatha, Repatha |
| Novo Nordisk INC | $205.29 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $150.17 | 2022-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $119.36 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $110.73 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $90.90 | 2021-2023 | Jardiance |
| Glaxosmithkline, LLC. | $67.59 | 2021-2025 | Shingrix, Trelegy Ellipta |
| Astellas Pharma US INC | $65.12 | 2023-2024 | Veozah |
| Abbott Laboratories | $56.78 | 2022-2024 | Freestyle Libre |
| Exact Sciences Corporation | $54.00 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Otsuka America Pharmaceutical, INC. | $46.41 | 2024 | Rexulti |
| Merck Sharp & Dohme LLC | $23.43 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dynavax Technologies Corporation | $23.32 | 2024 | Heplisav-B |
| Ibsa Pharma INC. | $22.69 | 2022 | |
| Corium, LLC | $21.22 | 2023 | Azstarys |
| Neos Therapeutics, LP | $20.16 | 2021 | |
| Dexcom, INC. | $18.38 | 2023 | Dexcom G6 Transmitter |
| Mylan Specialty L.P. | $16.35 | 2021 | |
| Eisai INC. | $16.05 | 2021 | |
| Adlon Therapeutics L.P. | $14.20 | 2021 | |
| Cranial Technologies, INC | $12.46 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrea Ford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.